Background: Regular treatment with inhaled salbutamol (seven to 14 days) increases airway responsiveness to allergen. OBJECTIVE: To assess the effect of salmeterol 50 μg twice daily for six days on the early asthmatic response to allergen (PC15). DESIGN: Double-blind, randomized, crossover trial comparing salmeterol with placebo (twice daily over six days) with one week or more washout. Forced expiratory volume in 1 s (FEV1) and allergen PC15 were measured 36 h after each treatment was discontinued. Setting: Tertiary care out-patient bronchoprovocation laboratory. Subjects: Fourteen atopic asthmatics well controlled with (n = 5) or without (n = 9) inhaled corticosteroids. Subjects did not use inhaled beta-agonists for at least two weeks before and during the trial. Results: FEV1 was slightly but significantly lower 36 h after the last dose of salmeterol versus placebo (3.28 ± 0.83 versus 3.40 ± 0.88 L, P = 0.032). Airway responsiveness to allergen increased by about half a doubling concentration (log10 PC15 2.71 ± 0.61 versus 2.85 ± 0.61, P = 0.047). Conclusion: A six-day treatment course of salmeterol 50 μg twice daily resulted in a slight decline in FEV1 and a modest increase in airway response to allergen at 36 h.
- Airway response
- Inhaled corticosteroids
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine